Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE-975 pembrolizumab with definitive chemoradiotherapy for esophageal carcinoma
2019-002006-51Phase 3Active
- Sponsor
- Merck & Co.
- Start
- Nov 2019
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in esophageal cancer comparing Pembrolizumab + definitive chemoradiotherapy with Placebo + definitive chemoradiotherapy (2 arms). Primary endpoint: Overall survival. Started Nov 2019; status: active.
02
Drugs
03
Conditions
esophageal cancer
Beyond the preview
Go deeper on 2019-002006-51.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002006-51.